Daher A, et al. - An open label randomized clinical trial was performed to assess the efficacy and safety of 3 treatment regimens using either one of two fixed dose artemisinin-based combinations or chloroquine in combination with a short course of primaquine (7–9 days: total dose 3–4.2 mg/kg) to treat Plasmodium vivax malaria in Brazil. Findings revealed the efficacy and safety of all three regimens that were tested with 42-day cure rates that meet World Health Organization criteria. In this population, the efficacy and safety of artemisinin-based combination therapy regimens offered the opportunity to treat all species of malaria with the same regimen. These could simplify protocols for malaria control programmes and potentially contribute to elimination of both vivax and falciparum malaria.